Fundraising FoxNucleo Tech
1 known investors
Find your way into Nucleo Tech
271 people in our graph can introduce you to the Nucleo Tech team.
Sign up to see every warm intro you have to Nucleo Tech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nucleo Tech team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
NucleoTech engineers BrainPortal carrier proteins that attach to therapeutic antibodies and oligonucleotides and transport them across the blood-brain barrier non-invasively, using a direct in vivo screening platform to test many candidates simultaneously. It advances internal CNS therapeutics and licenses its carriers to pharma and biotech partners.
Founders & leadership
UB
Uriah BekensteinCo-Founder & CEOUriah Bekenstein holds a Ph.D. in molecular neurobiology under Prof. Hermona Soreq and an M.Sc. under S. Kadener, with research focused on neurodegenerative conditions using molecular biology and biochemistry; he is a USPTO patent agent and Co-Founder & CEO of NucleoTech.
NC
Naftali CohenCo-Founder & CBO
AK
Adi KoplovitzCo-Founder & COOAdi Koplovitz is Co-Founder and COO of NucleoTech, which develops carrier proteins to transport therapeutics across the blood-brain barrier. He has background in strategy, market analysis, and financial modeling.
SD
Shachar DaganHead of ResearchShachar Dagan is a neuroscientist with 15 years of research experience in molecular neurobiology, viral vector development, and animal models. He brings expertise in genetic regulation of CNS cells, in vivo genetic engineering, and blood-brain barrier biology to his role as Head of Research at NucleoTech.
Investors · 1
Related companies · 1
Companies working in the same space as Nucleo Tech.
Frequently asked questions
- What does Nucleo Tech do?
- NucleoTech engineers BrainPortal carrier proteins that attach to therapeutic antibodies and oligonucleotides and transport them across the blood-brain barrier non-invasively, using a direct in vivo screening platform to test many candidates simultaneously. It advances internal CNS therapeutics and licenses its carriers to pharma and biotech partners.
- Who founded Nucleo Tech?
- Nucleo Tech was founded by Uriah Bekenstein, Naftali Cohen, Adi Koplovitz.
- Who are Nucleo Tech's investors?
- Nucleo Tech's investors include The Innovation Space.